Key Highlights of the Merger
- Merger Completion: Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) has officially completed its previously announced merger with Viskase Companies, Inc. The transaction was structured as an all-stock deal, with Viskase merging into a wholly owned subsidiary of Enzon.
- New Company Structure: Post-merger, Viskase has been converted into a limited liability company (now named Viskase Companies, LLC) under Delaware law.
- Combined Entity: The merged entity will operate as Viskase Holdings, Inc. and will focus on advancing the business operations of Viskase Companies, LLC, a leading worldwide producer of non-edible cellulosic, fibrous, and plastic casings used in the processing and packaging of meat and poultry products.
- Shareholder Ownership: After the closing of the merger, former Enzon shareholders will own approximately 45% of the combined company, while former Viskase shareholders will own about 55%.
- Stock Trading Information: The company’s common stock will temporarily trade on the OTCQB under the ticker symbol ENZND for the next 20 trading days. The CUSIP for the common stock is 293904 801.
Key Details for Shareholders
- Ownership Changes: The shift in ownership percentages (45% Enzon, 55% Viskase) following the merger is significant for both sets of shareholders, as it affects control and voting rights in the newly formed company.
- Company Focus: The combined company will prioritize expanding and enhancing Viskase Companies, LLC’s established business in food casings, which serves some of the world’s largest consumer products companies. This could lead to opportunities for revenue growth and increased market penetration.
- Temporary Ticker Symbol: Investors should note the change to “ENZND” as the temporary trading symbol for 20 days, which may affect trading liquidity and visibility in the short term.
Forward-Looking Statements and Risks
The announcement contains several forward-looking statements, which are subject to various risks and uncertainties, including but not limited to:
- Realization of Merger Benefits: There is no guarantee that the anticipated benefits (such as increased revenues, reduced expenses, improved earnings, and favorable tax treatment) will be realized.
- Potential Litigation: The combined company may face litigation related to the merger, which could impact its financial standing or reputation.
- Personnel Risks: The ability to retain and attract key personnel could be affected by the merger.
- Business Relationship Changes: The merger may cause adverse reactions or changes in relationships with customers, employees, or suppliers, potentially affecting financial performance.
- Uncertainty and External Risks: Other risks include business uncertainty, changes to existing relationships, legislative and regulatory developments, unexpected catastrophic events (such as geopolitical conflicts or terrorism), and other factors detailed in the company’s SEC filings.
About Viskase Companies, LLC and Viskase Holdings, Inc.
Viskase Companies, LLC is a global leader in the production of non-edible cellulosic, fibrous, and plastic casings for processed meat and poultry products, providing value-added support services to major consumer brands worldwide.
Viskase Holdings, Inc. (formerly Enzon Pharmaceuticals, Inc.) is now the publicly traded parent company of Viskase Companies, LLC and its subsidiaries.
Investor Contact
For further information, investors can contact:
Joseph D. King
Senior Vice President, General Counsel & Secretary
[email protected]
Disclaimer: This article contains forward-looking statements based on current expectations and beliefs of management. Actual results may differ materially from those projected. Investors are advised to review all risk factors and disclosures in the company’s filings with the SEC and consult with their financial advisors before making investment decisions. This article is for informational purposes only and does not constitute investment advice.
View ENZON PHARMACEUTICALS, INC. Historical chart here
